Reconsidering the role of blood-brain barrier in Alzheimer's disease: From delivery to target

被引:21
|
作者
Sousa, Joao Andre [1 ]
Bernardes, Catarina [1 ]
Bernardo-Castro, Sara [1 ,2 ]
Lino, Miguel [3 ]
Albino, Ines [3 ]
Ferreira, Lino [2 ,3 ]
Bras, Jose [4 ]
Guerreiro, Rita [4 ]
Tabuas-Pereira, Miguel [1 ,2 ]
Baldeiras, Ines [2 ,5 ]
Santana, Isabel [1 ,2 ,5 ]
Sargento-Freitas, Joao [1 ,2 ,3 ,5 ]
机构
[1] Ctr Hosp & Univ Coimbra, Dept Neurol, Coimbra, Portugal
[2] Univ Coimbra, Fac Med, Coimbra, Portugal
[3] Univ Coimbra, Ctr Neurosci & Cell Biol, Coimbra, Portugal
[4] Van Andel Inst, Dept Neurodegenerat Sci, Grand Rapids, MI USA
[5] Univ Coimbra, Ctr Innovat Biomed & Biotechnol CIBB, Coimbra, Portugal
来源
关键词
blood-brain barrier; nanomaterials; Alzheimer's disease; neurodegenerative diseases; amyloid clearance; genetic targeting; AMYLOID-BETA; MOUSE MODEL; NEUROVASCULAR DYSFUNCTION; DRUG-DELIVERY; THERAPEUTIC STRATEGIES; COGNITIVE IMPAIRMENT; P-GLYCOPROTEIN; CLEARANCE; RAGE; FLOW;
D O I
10.3389/fnagi.2023.1102809
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The existence of a selective blood-brain barrier (BBB) and neurovascular coupling are two unique central nervous system vasculature features that result in an intimate relationship between neurons, glia, and blood vessels. This leads to a significant pathophysiological overlap between neurodegenerative and cerebrovascular diseases. Alzheimer's disease (AD) is the most prevalent neurodegenerative disease whose pathogenesis is still to be unveiled but has mostly been explored under the light of the amyloid-cascade hypothesis. Either as a trigger, bystander, or consequence of neurodegeneration, vascular dysfunction is an early component of the pathological conundrum of AD. The anatomical and functional substrate of this neurovascular degeneration is the BBB, a dynamic and semi-permeable interface between blood and the central nervous system that has consistently been shown to be defective. Several molecular and genetic changes have been demonstrated to mediate vascular dysfunction and BBB disruption in AD. The isoform epsilon 4 of Apolipoprotein E is at the same time the strongest genetic risk factor for AD and a known promoter of BBB dysfunction. Low-density lipoprotein receptor-related protein 1 (LRP-1), P-glycoprotein, and receptor for advanced glycation end products (RAGE) are examples of BBB transporters implicated in its pathogenesis due to their role in the trafficking of amyloid-beta. This disease is currently devoid of strategies that change the natural course of this burdening illness. This unsuccess may partly be explained by our misunderstanding of the disease pathogenesis and our inability to develop drugs that are effectively delivered to the brain. BBB may represent a therapeutic opportunity as a target itself or as a therapeutic vehicle. In this review, we aim to explore the role of BBB in the pathogenesis of AD including the genetic background and detail how it can be targeted in future therapeutic research.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] The role of insulin resistance and APOE genotype on blood-brain barrier integrity in Alzheimer's disease
    Padovani, Alessandro
    Galli, Alice
    Bazzoli, Elena
    Tolassi, Chiara
    Caratozzolo, Salvatore
    Gumina, Bianca
    Benussi, Alberto
    Libri, Ilenia
    Outeiro, Tiago Fleming
    Pilotto, Andrea
    ALZHEIMERS & DEMENTIA, 2025, 21 (02)
  • [42] Latest Perspectives on Alzheimer's Disease Treatment: The Role of Blood-Brain Barrier and Antioxidant-Based Drug Delivery Systems
    Daraban, Bianca Sanziana
    Popa, Andrei Sabin
    Stan, Miruna S.
    MOLECULES, 2024, 29 (17):
  • [43] Blood-Brain Barrier Leakage in Early Alzheimer Disease
    Lecler, Augustin
    Fournier, Laure
    Diard-Detoeuf, Capucine
    Balvay, Daniel
    RADIOLOGY, 2017, 282 (03) : 923 - 924
  • [44] Delivery of opioid analgesics to the brain: the role of blood-brain barrier
    Mercadante, Sebastiano
    Arcuri, Edoardo
    GENE THERAPY AND MOLECULAR BIOLOGY, 2009, 13A : 82 - 90
  • [45] Translational strategies and systems biology insights for blood-brain barrier opening and delivery in brain tumors and Alzheimer's disease
    Song, Gefei
    Plumlee, Pierce
    Ahn, Ju Young
    Wong, Stephen T. C.
    Zhao, Hong
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 167
  • [46] Blood-brain barrier delivery
    Pardridge, William M.
    DRUG DISCOVERY TODAY, 2007, 12 (1-2) : 54 - 61
  • [47] Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." The blood-brain barrier: A physical and conceptual challenge
    Hachinski, Vladimir
    Lee, Ting-Yim
    ALZHEIMERS & DEMENTIA, 2009, 5 (05) : 435 - 436
  • [48] Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients
    Claudio, L
    ACTA NEUROPATHOLOGICA, 1996, 91 (01) : 6 - 14
  • [49] The role of the cell surface LRP and soluble LRP in blood-brain barrier a clearance in Alzheimer's Disease
    Deane, R.
    Sagare, A.
    Zlokovic, B. V.
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (16) : 1601 - 1605
  • [50] Possible effects of Porphyromonas gingivalis on the blood-brain barrier in Alzheimer's disease
    Olsen, Ingar
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2021, 19 (11) : 1367 - 1371